Wesana Health Holdings Inc
Change company Symbol lookup
Select an option...
WSNAF Wesana Health Holdings Inc
ZEUS Olympic Steel Inc
EJH E-Home Household Service Holdings Ltd
AMZN Amazon.com Inc
BGTTF Goat Industries Ltd
BRDS Bird Global Inc
GHM Graham Corp
DRMA Dermata Therapeutics Inc
VGAS Verde Clean Fuels Inc
CURV Torrid Holdings Inc
Go

Based in Canada

Wesana Health Holdings Inc is a Canada-based life science company. The Company is engaged in development and delivery of psychedelic and naturally sourced therapies to treat traumatic brain Injury related depressive disorder, anxiety and migraines through drug development and predictive diagnostics. The Company is also engaged in care development through its therapies and patent-pending protocols, and in care delivery through activating a multidisciplinary, technology-supported clinical model. Its SANA-013 is a novel composition and method of use that provides sustained effects and benefit over time. The Company’s novel and proprietary depression treatment protocol that includes a single high dose of psilocybin followed by a maintenance regimen of a micro dose of psilocybin combined with cannabidiol, significantly reduced depressive behaviors in a validated animal model.

Closing Price: $0.036

Day's Change: 0.00 (0.00%)

Bid: --

Ask: --

B/A Size: --

Day's High: --

Day's Low: --

Volume (Heavy Day) Volume: 19,050 10-day average volume: 19,346: 19,050

CytomX shares surge more than 50% on Moderna partnership

5:11 pm ET January 5, 2023 (MarketWatch) Print

CytomX Therapeutics Inc. (CTMX) shares soared more than 50% in the extended session Thursday after the small biotech company announced a partnership with Moderna Inc. (MRNA) CytomX shares were last up 57% after hours, following a 7.2% rise to close the regular session at $1.79. Under the agreement, CytomX gets a $35 million up-front payment, and is eligible for up to $1.2 billion in additional payments to research and develop "messenger RNA-based conditionally activated therapeutics" with Moderna. The company also reported "encouraging clinical activity" in its CX-2029 clinical trials in partnership with AbbVie Inc. (ABBV)

-MarketWatch

(END) Dow Jones Newswires

January 05, 2023 17:11 ET (22:11 GMT)

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for varies.

Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and